Nasal septum perforation in a breast cancer patient treated with bevacizumab

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1901-1902

  Pinto Marín, Alvaro ^a   Redondo Sanchez A ^a   Espinosa Arranz, E ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NODULE; LYMPHADENECTOMY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NOSE SEPTUM PERFORATION; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 71049169180     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp451     Document Type: Article

References (4)

1. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 2009; 10: 559-568.
2. Miller K, Wang L, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
3. Hickin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
4. Traina TA, Norton L, Drucker K, Singh B. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist 2006; 11: 1070-1071.